Your browser doesn't support javascript.
loading
Biotransformation Pathways and Metabolite Profiles of Oral [14C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors.
Pusalkar, Sandeepraj; Zhou, Xiaofei; Li, Yuexian; Cohen, Lawrence; Yang, Jun Johnny; Balani, Suresh K; Xia, Cindy; Shyu, Wen Chyi; Lu, Chuang; Venkatakrishnan, Karthik; Chowdhury, Swapan K.
Afiliación
  • Pusalkar S; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan sandeepraj.pusalkar@takeda.com.
  • Zhou X; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan.
  • Li Y; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan.
  • Cohen L; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan.
  • Yang JJ; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan.
  • Balani SK; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan.
  • Xia C; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan.
  • Shyu WC; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan.
  • Lu C; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan.
  • Venkatakrishnan K; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan.
  • Chowdhury SK; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan.
Drug Metab Dispos ; 48(3): 217-229, 2020 03.
Article en En | MEDLINE | ID: mdl-31911485
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Pirimidinas / Azepinas / Biotransformación / Inhibidores de Proteínas Quinasas / Aurora Quinasa A / Neoplasias Tipo de estudio: Guideline Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Drug Metab Dispos Asunto de la revista: FARMACOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Pirimidinas / Azepinas / Biotransformación / Inhibidores de Proteínas Quinasas / Aurora Quinasa A / Neoplasias Tipo de estudio: Guideline Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Drug Metab Dispos Asunto de la revista: FARMACOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Japón